<DOC>
	<DOCNO>NCT02117518</DOCNO>
	<brief_summary>It well establish CD8 CD4 T cell reactive define islet antigen associate initiation progression Type 1 Diabetes ( T1D ) . In previous work , demonstrate possible redirect T cell pathogenic T cell via chimeric peptide/MHC/CD3-zeta receptor peptide-specific manner prevent , inhibit diabetes NOD mouse . In study intend extend approach T cell T1D patient . Working hypothesis : Beta cell-reactive CD8 T cell human T1D patient immuno-targeted gene-modified cytotoxic T lymphocytes ( CTLs ) . Aims : Our major aim demonstrate , set ex-vivo experiment , immunotargeting T cell derive T1D patient Ziv Medical Center . To end stimulate expand autoreactive CD8 cell blood sample T1D patient target , ex-vivo , genetically-reprogrammed CTLs present blood sample .</brief_summary>
	<brief_title>Selective Immunotargeting Pathogenic CD8 T Cells Type 1 Diabetes Patients</brief_title>
	<detailed_description>To obtain proof-of-principle approach initiate tight collaboration Laboratory Immunology MIGAL Galilee Research Institute , Kiryat Shmona ( MIGAL ) Breinin Center Type 1 Diabetes Endocrinology Ziv Medical Center Safed ( Ziv ) . In study first identify carrier HLA-A0201 allele among pediatric young adult T1D patient Ziv . We screen T cell pool peripheral blood sample patient CD8 T cell reactive 3 know HLA-A0201-binding peptide associated autoreactivity T1D : Insulin beta chain 10-18 , IGRP 265-73 IGRP 222-230 . The influenza virus-derived peptide MP 58-66 serve reference . Next isolate polyclonal CD8 T cell blood sample patient , activate expand ex-vivo transfect via electroporation in-vitro-transcribed mRNA encode respective peptide/MHC/CD3-zeta construct ( ) . We perform co-culture experiment assess ability mRNA-transfected T cell kill autoreactive T cell patient peptide-selective manner .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Children young adult , age 025 diagnosed T1D 3 year prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>autoreactive T cell</keyword>
	<keyword>beta cell peptide</keyword>
	<keyword>genetically modify T cell</keyword>
	<keyword>mRNA electroporation</keyword>
</DOC>